Fri.May 24, 2019

Remove blogging-pricing
article thumbnail

Bio Roundup: Zolgensma Watch, Brain Cancer Blues, Peloton Payout & More

Xconomy

Patients, doctors, family members, and drug-price watchdogs continued to wait for the expected approval of Zolgensma , a Novartis (NYSE: NVS ) gene therapy for the rare inherited disease spinal muscular atrophy. Originally developed at a children’s hospital in Ohio , Zolgensma will be a litmus test for the nascent field.

Pricing 86